Compare · LLY vs ZYNE
LLY vs ZYNE
Side-by-side comparison of Eli Lilly and Company (LLY) and Zynerba Pharmaceuticals Inc. (ZYNE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and ZYNE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY carries a market cap of $1.33T.
- LLY has hit the wire 44 times in the past 4 weeks while ZYNE has been quiet.
- LLY has more recent analyst coverage (25 ratings vs 0 for ZYNE).
- Company
- Eli Lilly and Company
- Zynerba Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $1.33T
- -
- 1M return
- +14.11%
- -
- 1Y return
- +37.41%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2015
- News (4w)
- 44
- 0
- Recent ratings
- 25
- 0
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Zynerba Pharmaceuticals Inc.
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It improves the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.
Latest LLY
- Director Jamere Jackson was granted 168 shares, increasing direct ownership by 2% to 9,861 units (SEC Form 4)
- Director Jon R Moeller was granted 168 shares, increasing direct ownership by 55% to 473 units (SEC Form 4)
- Director William G Kaelin Jr was granted 168 shares, increasing direct ownership by 0.76% to 22,139 units (SEC Form 4)
- Director Kimberly H Johnson was granted 168 shares, increasing direct ownership by 5% to 3,452 units (SEC Form 4)
- Director Carolyn R Bertozzi was granted 178 shares, increasing direct ownership by 9% to 2,178 units (SEC Form 4)
- Director Katherine Baicker was granted 168 shares, increasing direct ownership by 0.71% to 23,815 units (SEC Form 4)
- Director Mary Lynne Hedley was granted 168 shares, increasing direct ownership by 7% to 2,430 units (SEC Form 4)
- Director Gabrielle Sulzberger was granted 171 shares, increasing direct ownership by 6% to 3,188 units (SEC Form 4)
- Director Juan R Luciano was granted 179 shares, increasing direct ownership by 1% to 17,148 units (SEC Form 4)
- Director J Erik Fyrwald was granted 175 shares, increasing direct ownership by 0.23% to 75,719 units (SEC Form 4)
Latest ZYNE
- SEC Form SC 13G/A filed by Zynerba Pharmaceuticals Inc. (Amendment)
- SEC Form 15-12G filed by Zynerba Pharmaceuticals Inc.
- SEC Form EFFECT filed by Zynerba Pharmaceuticals Inc.
- Jones Kenneth T was granted 30,000 shares, closing all direct ownership in the company (SEC Form 4)
- Stephenson Pamela closing all direct ownership in the company (SEC Form 4)
- Fickenscher James E was granted 170,000 shares, closing all direct ownership in the company (SEC Form 4)
- Sebree Terri B was granted 170,000 shares, closing all direct ownership in the company (SEC Form 4)
- Federici William J closing all direct ownership in the company (SEC Form 4)
- Rosenberger Brian was granted 120,000 shares, closing all direct ownership in the company (SEC Form 4)
- Cooper Warren D closing all direct ownership in the company (SEC Form 4)